Scinai Immunotherapeutics Ltd (SCNI) FinancialsSCNIScinai Immunotherapeutics Ltd

Evaluating the bottom line, Scinai Immunotherapeutics Ltd maintains a gross margin of -272.17%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -466.52%, while the net margin is -435.43%. These profitability ratios, combined with a Return on Equity (ROE) of -62.36%, provide a clear picture of how effectively SCNI converts its operational activities into shareholder value.

In the context of the broader market, SCNI competes directly with industry leaders such as ATPC and PAVS. With a market capitalization of $615.20K, it holds a significant position in the sector. When comparing efficiency, SCNI's gross margin of -272.17% stands against ATPC's 85.96% and PAVS's 19.98%. Such benchmarking helps identify whether Scinai Immunotherapeutics Ltd is trading at a premium or discount relative to its financial performance.

The financial performance shows a troubling trend with a net income loss of -$2,003,000 in Q2 2026 and a gross margin of -272.17%. The company has also seen a decline in cash reserves, from $2.1 million in 2024 to $1.8 million in 2025, indicating liquidity challenges.